Double-blind, prospective, multicenter trial comparing ceftazidime with moxalactam in the treatment of serious gram-negative infections.

Ceftazidime is a new antimicrobial agent possessing excellent in vitro activity against most members of the family Enterobacteriaceae and against Pseudomonas aeruginosa. We conducted a double-blind, prospective, multicenter trial to compare ceftazidime with moxalactam in the treatment of serious gra...

Celý popis

Podrobná bibliografie

Vydáno v:	Antimicrob Agents Chemother
Hlavní autoři:	Joshi, M, Anthony, W C, Tenney, J H, Drusano, G L, Caplan, E S, Standiford, H C, Henson, A, Warren, J W
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	American Society for Microbiology (ASM) 1986
Témata:	Research Article
On-line přístup:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC176442/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/3530128/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.30.1.90
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!